期刊文献+

某眼科医院2018年~2020年降眼压药物的使用分析

Analysis on the use of intraocular pressure-lowering drugs in an eye hospital in recent years
下载PDF
导出
摘要 目的了解降眼压类滴眼液使用情况,分析药物疗效及使用的合理性,探讨临床用药的特点和趋势。方法对某院2018年~2020年对治疗降眼压类滴眼液的用药频度(DDDs)、日均费用(DDC)、药物利用指数(DUI)、序号比(B/A)、复合年均增长率(CAGR)进行统计分析。结果降眼压类药物中复方制剂和单剂量包装药品使用量增多,其它制剂相应减少。结论未来降眼压药物的发展方向为:毒副作用小,疗效好的复方制剂,单剂量包装以及新药研发。 Objective To understand the use of intraocular pressure-lowering eye drops,to analyze the efficacy and rationality of drug use,and to explore the characteristics and trends of clinical drug use.Methods The medication frequency(DDDs),daily average cost(DDC),drug utilization index(DUI),serial number ratio(B/A)and compound annual growth rate(CAGR)of ocular hypotensive eye drops in a hospital from 2018 to 2020 were analyzed statistically.Results The usage of compound preparations and single dose packaging drugs increased,while other preparations decreased correspondingly.Conclusion The future development direction of antihypertensive drugs is:compound preparations with small side effects and good curative effect,single dose packaging and new drug research and development.
作者 邓丽珠 钟健文 DENG Li-zhu;ZHONG Jian-wen(Zhongshan ophthalmic center of Sun Yat-sen University,Guangzhou 510000,China)
出处 《中国处方药》 2022年第3期60-62,共3页 Journal of China Prescription Drug
关键词 降眼压类滴眼液 用药频度 日均费用 复合年均增长率 序号比 药物利用指数 Ocular hypotensive eye drops Medication frequency Daily drugs cost Compound annual growth rate Serial number ratio Drug utilization index
  • 相关文献

参考文献8

二级参考文献63

  • 1中华医学会眼科学分会青光眼学组.《中国青光眼临床工作指南》(2005)公布[J].中华眼科杂志,2005,41(12):1140-1143. 被引量:61
  • 2Kobayashi S.Characterization of drugs for treating glaucoma whichare prostaglandin analogs with a stem name of "-Proston " or"-prost"[J]. J Med Association of Nippon Med Sch,2012,8(2):134-142. 被引量:1
  • 3Takagi Y,Nakajima T,Shimazaki A,et al.Pharmacologicalcharacteristics of AFP-168(tafluprost),a new prostanoid FPreceptor agonist,as an ocular hypotensive drug[J].Exp Eye Res,2004,78(4);767-776. 被引量:1
  • 4Kurashima H,Asai Y,Aihara M,et al.Ocular hypotensive effectof tafluprost in latanoprost low-responder cynomolgus monkeys[J].J Glaucoma,2012,21(2):123-128. 被引量:1
  • 5Kuwayama Y,Komemushi S.Phase III Confirmatory Study of0.0015% DE085(Tafluprost)Ophthalmic Solution as Comparedto 0.005% Latanoprost Ophthalmic Solution in Patients withOpen-Angle Glaucoma or Ocular Hypertension[J].AtarashiiGanka(Journal of the eye),2008,25(11):1595-1602. 被引量:1
  • 6Neil T Choplin,Diane C Lundy[M].Atlas of Glaucoma,ed I.UK:Martin Dunitz Ltd,1998:39-55. 被引量:1
  • 7European Glaucoma Society.Terminology and Guidelines forGlaucoma.3rd Edition[M].Savona,Italy:Editrice DOGMA,s.r.1.2008:118. 被引量:1
  • 8Hellberg MR,Sallee VL,Mclaughlin MA,et al.PreclinicalEfficacy of Travoprost,a Potent and Selective FP Prostaglandin Receptor Agonist[J].J Ocular Pharmacol Therap,2001,17(5):421432. 被引量:1
  • 9Sharif NA,Kelly CR,Crider JY,et al.Ocular hypotensive FPprostaglandin(PG)analogs:PG receptor subtype binding affinitiesand selectivities,and agonist potencies at FP and other PGreceptors in cultured cells[J].J Ocul Pharmacol Th,2003,19(6):501-515. 被引量:1
  • 10American Academy of Ophthalmology.Preferred Practice Pattern:Primary Open-Angle Glaucoma[M].San Francisco,CA:American Academy of Ophthalmology,2010. 被引量:1

共引文献91

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部